ClinicalTrials.gg
RecruitingNCT06834724Updated Nov 18, 2026

Clinical Outcomes of Continuous Positive Airway Pressure Treatment in People With Obstructive Sleep Apnea and Chronic Pain

An observational study in Chronic Pain and Obstructive Sleep Apnea, sponsored by Vrije Universiteit Brussel. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Vrije Universiteit Brussel · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Nov 18, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Chronic Pain by Vrije Universiteit Brussel — 4 open to participants now, 4 under way, none of them phase 3. Chronic Pain · Vrije Universiteit Brussel.

Started
2025
with 2 others
Observational
6 of 16
2 open now
Registered
14th of 16
by date

Among the 16 studies in Chronic Pain by Vrije Universiteit Brussel, this one is one of 3 that started in 2025, is one of 6 observational ones, and was the 14th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

4 of the 16 studies in Chronic Pain by Vrije Universiteit Brussel are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Chronic Pain by Vrije Universiteit Brussel, or all of them as a file.
02

Study summary

The bidirectional link between sleep and pain is widely accepted. However, studies investigating obstructive sleep apnoea (OSA) and chronic pain remain scarce, especially in the context of continuous positive airway pressure (CPAP) therapy. In this study, people recently diagnosed with OSA who are starting CPAP therapy complete questionnaires at baseline and at 3- and 6-month follow-up, and device-recorded CPAP adherence data are collected at routine clinical follow-up. Data from people with and without chronic pain are collected to answer several clinically relevant questions. The primary questions investigate: 1) the association between CPAP use and pain intensity at 3-month follow-up; 2) the association between the baseline apnoea-hypopnoea index (AHI) and pain intensity at 3-month follow-up; and 3) differences in device-recorded CPAP use between people with and without chronic pain and with and without comorbid insomnia (COMISA). Secondary questions investigate CPAP adherence, the prevalence of chronic pain, the relevance of comorbid insomnia, and clinical outcomes of CPAP therapy in people with chronic pain.

Read the detailed description

OVERVIEW In this study, participants with obstructive sleep apnoea (OSA) who start continuous positive airway pressure (CPAP) treatment complete questionnaires at baseline and at two follow-up time points (3 and 6 months after the start of CPAP treatment). Together with device-recorded CPAP adherence data and data from the polysomnography every participant undergoes before starting CPAP, this allows us to investigate relevant outcomes of CPAP therapy in people with chronic pain (CP).

- Recruitment continues until 200 participants are enrolled, with the aim of including approximately 80 participants with CP.

GROUPS - Participants are classified at baseline as OSA only; OSA with CP; OSA with comorbid insomnia (COMISA, Insomnia Severity Index >= 15); or COMISA with CP.

CPAP ADHERENCE

  • Device-recorded CPAP use is taken from CPAP device reports, which cover the period from the start of CPAP therapy to the date of the readout. Readouts take place at routine clinical appointments.
  • In routine care, a titration (in-hospital polysomnography or ambulatory polygraphy, depending on OSA severity) is planned approximately 1 month after the start of CPAP therapy, followed by a device readout 1 week later and a further readout approximately 2.5 months later. Because of waiting lists, the actual timing varies between participants.
  • 3-month adherence: the readout closest to 90 days after the start of CPAP therapy, with a minimum of 60 days of monitoring (excluding the early readout shortly after titration). Used for analyses of adherence and of pain at 3-month follow-up.
  • 6-month adherence: the readout closest to 180 days after the start of CPAP therapy. Used for analyses of pain at 6-month follow-up and as a measure of longer-term adherence.
  • If two readouts are equally close, the earlier one is used. If a readout is invalid due to device malfunction or a required device change, the next closest valid readout is used. The length of the monitoring period is included as a covariate in all analyses of adherence.
  • Mean nightly CPAP use is calculated over all nights in the monitoring period, including nights without use.
  • Adherence = CPAP use >= 4 hours per night on >= 70% of monitored nights; non-adherence = not meeting this criterion. As a secondary definition, the proportion of participants meeting the Belgian reimbursement criterion (mean use >= 4 hours per night) will also be reported.
  • Sensitivity analyses will exclude readouts obtained more than 30 days before or after the target time point (i.e., outside 60-120 days for 3-month adherence and outside 150-210 days for 6-month adherence).

PRIMARY RESEARCH QUESTIONS

  • P1 (longitudinal): Is average CPAP use (hours/night, continuous) associated with average pain intensity at 3-month follow-up in people with OSA and CP?
  • P2 (longitudinal): Is AHI at baseline associated with average pain intensity at 3-month follow-up in people with OSA and CP?
  • P3: Does device-recorded CPAP use (hours/night) differ between people with and without CP and with and without comorbid insomnia (OSA only, OSA + CP, COMISA, COMISA + CP)? SECONDARY RESEARCH QUESTIONS - CROSS-SECTIONAL
  • S1: Do the proportion of nights with >= 4 hours of CPAP use and the proportion of adherent participants (3-month adherence), and CPAP use and adherence at 6 months, differ between OSA only, OSA + CP, COMISA and COMISA + CP?
  • S2: What is the prevalence of CP in patients with clinically relevant OSA in a sleep clinic setting?
  • S3: Is there a difference in average pain intensity at baseline between people with OSA + CP and people with COMISA + CP?

SECONDARY RESEARCH QUESTIONS - LONGITUDINAL

  • S4: What are the short-term (3 months) and long-term (6 months) clinical outcomes (average pain intensity, fatigue, sleepiness, sleep quality, depression, anxiety, quality of life) of CPAP treatment in patients with clinically relevant OSA and CP, and do these outcomes (excluding pain intensity) differ from those in patients with OSA without CP?
  • S5: Does average pain intensity at 3- and 6-month follow-up differ between adherent and non-adherent patients with OSA and CP?
  • S6: Is average pain intensity at baseline a predictor of device-recorded CPAP adherence in people with OSA and CP?
  • S7: Is there a difference in self-reported health status with CPAP therapy at 3- and 6-month follow-up between people with clinically relevant OSA with and without CP?
  • S8: Is average CPAP use (hours/night, continuous) associated with average pain intensity at 6-month follow-up in people with OSA and CP?
  • S9: Is AHI at baseline associated with average pain intensity at 6-month follow-up in people with OSA and CP?

EXPLORATORY RESEARCH QUESTIONS

  • E1: Is there a difference in pain outcomes at 3- and 6-month follow-up between people with COMISA + CP and people with OSA + CP? SENSITIVITY AND SUBGROUP ANALYSES
  • Data for people with headaches and other chronic pain will be analysed separately, as headaches are a common direct consequence of OSA.

PUBLICATIONS

- Results will be reported in several publications grouped by theme (baseline characteristics, CPAP adherence, and pain and clinical outcomes of CPAP therapy). Each publication will refer to this registration and state which of the registered research questions it addresses.

REGISTRATION AMENDMENT (NOVEMBER 2026)

  • This registration was amended during ongoing recruitment. As of 30 September 2026 (last data check), 150 participants had been recruited, 139 had reached the 3-month follow-up, and 85 of these (61%) had completed at least the Brief Pain Inventory at 3 months. Baseline questionnaire data had been extracted for 79 participants, of whom 34 met criteria for CP; 21 of the 30 participants with CP who had reached the 3-month follow-up had completed the follow-up questionnaire.
  • Because questionnaire completion at follow-up was lower than anticipated, device-recorded CPAP adherence (available for all participants) was added as a primary outcome (P3) and secondary outcomes (S1, including adherence at 6 months), replacing the former secondary question on CPAP use at 3-month follow-up. Rules for selecting device readouts were defined in consultation with the sleep laboratory, based on the routine follow-up schedule.
  • Further changes: adherence in S6 is now based on device-recorded data; S4 was extended to compare clinical outcomes between participants with and without CP; the comparison of pain outcomes between COMISA + CP and OSA + CP was reclassified as exploratory (E1) because of small expected subgroups; the definition of non-adherence was corrected; and the anticipated enrollment was updated from 80 (target number with CP) to 200 (total enrollment).
  • No analyses of associations between exposures and outcomes, and no comparisons of CPAP adherence between groups, had been performed before this amendment.
03

Conditions studied

  • Chronic Pain
  • Obstructive Sleep Apnea

Keywords

  • Chronic pain
  • Obstructive sleep apnoea
  • Obstructive sleep apnea
  • CPAP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The target group for the study consists of adult, Dutch, French or Englisch speaking patients who have been referred to the sleep clinic. These patients have been diagnosed with OSA and will start to receive CPAP treatment. They are included independent of their chronic pain status but some analyses will be done in sub-groups.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 18 years of age or older
  • Participants must be able to read and write in Dutch, French or English
  • Participants must be diagnosed with OSA and newly start CPAP treatment:
  • AHI ≥ 15
  • Prescribed CPAP for the first time as a treatment for their OSA
  • Participants must have read and signed the ICF

Exclusion criteria

Exclusion Criteria:

  • Participants who are currently receiving CPAP treatment or have had a CPAP treatment in the last year
  • Participant receiving CPAP for other conditions than OSA (e.g. Central Sleep Apnoea)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • CPAP group

    Adults with clinically relevant obstructive sleep apnoea (AHI ≥ 15) newly starting CPAP therapy as part of standard care, with or without chronic pain. For analyses, participants are classified at baseline into four subgroups: OSA only; OSA with chronic pain; OSA with comorbid insomnia (COMISA, Insomnia Severity Index ≥ 15); and COMISA with chronic pain.

    Other: Standard OSA care

Interventions

  • OtherStandard OSA care

    All people will undergo standard care.

06

What researchers measure

Primary outcomes

  1. Average Pain during last 1 week

    Participants are asked for the average pain they had during the last 1 week. They answer on a scale for 0-10 with 0 being no pain and 10 being the worst pain ever. This is a single question taken from the Brief Pain Inventory

    Time frame: 3-months after initiation of CPAP therapy

  2. Device-recorded CPAP use at 3 months

    Mean nightly CPAP use (hours/night, averaged over all nights in the monitoring period including nights without use), from the CPAP device readout closest to 90 days after the start of CPAP therapy (minimum 60 days of monitoring). Compared between participants with and without chronic pain and with and without comorbid insomnia (Insomnia Severity Index \>= 15), analysed as a 2x2 design (pain x insomnia) including their interaction, adjusted for age, sex, AHI, BMI and length of the monitoring period. Readout rules and sensitivity analyses are described in the Detailed Description.

    Time frame: From the start of CPAP therapy to the device readout closest to 3 months (90 days)

Secondary outcomes

  1. Prevalence of chronic pain in people with OSA undergoing CPAP treatment

    Chronic pain defined as pain anywhere in the body that is present every day or most days for 3 months or longer and that regularly impairs quality of life or ability to do activities (leisure, work).

    Time frame: Baseline

  2. Average Pain during last 1 week

    Participants are asked for the average pain they had during the last 1 week. They answer on a scale for 0-10 with 0 being no pain and 10 being the worst pain ever. This is a single question taken from the Brief Pain Inventory.

    Time frame: 6-months after initiation of CPAP therapy

  3. Fatigue (Mental and Physical)

    Measured using the Brugmann Fatigue scale - 0-12 for each subscale (Mental fatigue and physical fatigue with 0 indicating no fatigue and 12 severe fatigue)

    Time frame: 3 and 6 months after initiation of CPAP therapy

  4. Sleepiness

    Measured using the Epworth sleepiness scale - 0-24 with 0 indicating no sleepiness and 24 severe sleepiness.

    Time frame: 3 and 6 months after initiation of CPAP therapy

  5. Subjective sleep quality

    Measured using the Pittsburgh Sleep quality index total score (0-21 with 0 indicating good sleep quality and 21 very bad sleep quality)

    Time frame: 3 and 6 months after initiation of CPAP therapy

  6. Depression

    Measured using the depression subscale of the Hospital Anxiety and Depression Scale - 0-21 with 0 being no depressive symptomatology and 21 being severe depressive symptomatology

    Time frame: 3 and 6 months after initiation of CPAP therapy

  7. Anxiety

    Measured using the anxiety subscale of the Hospital Anxiety and Depression Scale - 0-21 with 0 being no anxiety and 21 being severe anxiety

    Time frame: 3 and 6 months after initiation of CPAP therapy

  8. Self-reported health status

    Measured using the Short Form 36 (SF-36) subscales with 0 indicating worse status and 100 indicating better health status in a domain

    Time frame: 3 and 6 months after initiation of CPAP therapy

  9. CPAP adherence rate at 3 months

    Percentage of monitored nights with \>= 4 hours of CPAP use, and CPAP adherence (yes/no; adherence = \>= 4 hours on \>= 70% of monitored nights, non-adherence = not meeting this criterion), from the device readout closest to 90 days after the start of CPAP therapy (minimum 60 days of monitoring). Compared between participants with and without chronic pain and with and without comorbid insomnia, with the same analysis and covariates as the primary outcome on device-recorded CPAP use.

    Time frame: From the start of CPAP therapy to the device readout closest to 3 months (90 days)

  10. Device-recorded CPAP use and adherence at 6 months

    Mean nightly CPAP use (hours/night, including nights without use), percentage of monitored nights with \>= 4 hours of use, and CPAP adherence (yes/no, as defined for the 3-month adherence outcome), from the device readout closest to 180 days after the start of CPAP therapy. Compared between participants with and without chronic pain and with and without comorbid insomnia, with the same analysis and covariates as the primary outcome on device-recorded CPAP use.

    Time frame: From the start of CPAP therapy to the device readout closest to 6 months (180 days)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Apr 2027, 25 months after the start.

Of 337 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's planned 25 months is close to that.

Counting every sponsor, half of 363 studies reached it within 24 months; a quarter within 12 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Dec 2025 → Apr 2027 and completion Apr 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2025
First posted
Feb 19, 2025
StartActual
Mar 10, 2025
Primary completionEst.
Apr 2027was Dec 2025
CompletionEst.
Aug 2027was Apr 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2025→Apr 2027
Nov 18, 2026
Study completion
Apr 2026→Aug 2027
Nov 18, 2026
Enrollment
80→200
Nov 18, 2026
Primary outcomes
1 added
What changed in the outcomes
  • AddedDevice-recorded CPAP use at 3 monthsTime frame: From the start of CPAP therapy to the device readout closest to 3 months (90 days)
Nov 18, 2026
Secondary outcomes
1 edited, 1 added, 1 description edited
What changed in the outcomes
  • EditedCPAP adherence rate at 3 monthsTime frame: 3-months after initiation of CPAP therapy → From the start of CPAP therapy to the device readout closest to 3 months (90 days)
  • AddedDevice-recorded CPAP use and adherence at 6 monthsTime frame: From the start of CPAP therapy to the device readout closest to 6 months (180 days)
  • DescriptionAverage Pain during last 1 week: how it is measured was reworded
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Dec 2025→Apr 2027
    Study completion Apr 2026→Aug 2027
    Enrollment 80→200
    Primary outcomes 1 added
    What changed in the outcomes
    • AddedDevice-recorded CPAP use at 3 monthsTime frame: From the start of CPAP therapy to the device readout closest to 3 months (90 days)
    Secondary outcomes 1 edited, 1 added, 1 description edited
    What changed in the outcomes
    • EditedCPAP adherence rate at 3 monthsTime frame: 3-months after initiation of CPAP therapy → From the start of CPAP therapy to the device readout closest to 3 months (90 days)
    • AddedDevice-recorded CPAP use and adherence at 6 monthsTime frame: From the start of CPAP therapy to the device readout closest to 6 months (180 days)
    • DescriptionAverage Pain during last 1 week: how it is measured was reworded
    + 4 other changes: verification date, oversight details, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06834724
Responsible party
Olivier Mairesse (Professor, Vrije Universiteit Brussel) — Principal investigator
First posted
Feb 19, 2025
Start date
Mar 10, 2025
Primary completion
Apr 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Nils Runge, MSc
Contact
nils.arno.andreas.runge@vub.be
+32 2 477 44 20
Olivier Mairesse, PhD
Contact
Olivier.mairesse@vub.be
+32 2 629 25 16

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion